ArticlePLoS pathogens2026
IL-22 promotes the establishment of chronic gammaherpesvirus infection by supporting the germinal center response.
Article in PLoS pathogens, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
Gammaherpesviruses, including human Epstein-Barr Virus (EBV) and Kaposi's Sarcoma-associated Herpesvirus (KSHV), establish lifelong latent infections that contribute to multiple cancers and Multiple Sclerosis. These viruses colonize naïve B cells and drive a robust, polyclonal germinal center response to expand the latent viral reservoir and establish lifelong infection in memory B cells. Despite the clinical burden of these viruses, the host factors that support chronic infection remain poorly defined. Interleukin-22 (IL-22) is a critical cytokine traditionally recognized for its protective roles in bacterial and fungal defense; however, its involvement in gammaherpesvirus pathogenesis has not been explored. Using murine gammaherpesvirus 68 (MHV68) as a tractable in vivo model, we identify IL-22 as a host factor that promotes the establishment of chronic gammaherpesvirus infection. MHV68 infection triggers robust IL-22 production across multiple anatomical sites and immune cell populations. Although IL-22 deficiency did not affect acute viral replication, IL-22-/- mice exhibited a sustained reduction in latent viral burden within both the spleen and peritoneal cavity. This phenotype was accompanied by impaired germinal center B cell and T follicular helper cell responses, reduced plasma-cell expansion, diminished virus-specific antibody responses, and attenuated polyclonal autoreactive antibody production. Furthermore, IL-22 deficiency was associated with reduced systemic BAFF levels, suggesting that IL-22 contributes to the establishment of a germinal center microenvironment that supports chronic infection. Together, these findings identify IL-22 as a previously unrecognized regulator of chronic gammaherpesvirus infection and reveal a role for this cytokine in coordinating germinal center responses, humoral immunity, and latent reservoir establishment, providing new insight into how host immune pathways contribute to lifelong gammaherpesvirus infection.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.